Remternetug
瑞美奈塔单抗
Report date: 2026/03/04 20:01:44
Base Information
Drug NameRemternetug
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[18]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A
Develop Information
Active CompaniesWashington University School Of MedicineEli Lilly And CompanyLilly Suzhou Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A